Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Growth 2025-2031

The global Chemotherapy Induced Peripheral Neuropathy Treatment market size is predicted to grow from US$ 1853 million in 2025 to US$ 2726 million in 2031; it is expected to grow at a CAGR of 6.6% from 2025 to 2031.

CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.

There are no approved therapies to combat the debilitating symptoms of CIPN now. Current alternatives include Palliative care using antidepressants, antiepileptic drugs, or opioids, all of which have well known adverse side effects.

Americas is the largest market with about 47% market share. Europe is follower, accounting for about 27% market share.

The key players are Aptinyx Inc, Asahi Kasei Pharma Corp, Regenacy Pharmaceuticals, MAKScientific LLC, Metys Pharmaceuticals AG, Nemus Bioscience Inc, PledPharma, Sova Pharmaceuticals Inc, DermaXon LLC, Kineta Inc, Krenitsky Pharmaceuticals Inc, PeriphaGen, Apexian Pharma, WinSanTor etc.

LP Information, Inc. (LPI) ' newest research report, the “Chemotherapy Induced Peripheral Neuropathy Treatment Industry Forecast” looks at past sales and reviews total world Chemotherapy Induced Peripheral Neuropathy Treatment sales in 2024, providing a comprehensive analysis by region and market sector of projected Chemotherapy Induced Peripheral Neuropathy Treatment sales for 2025 through 2031. With Chemotherapy Induced Peripheral Neuropathy Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Chemotherapy Induced Peripheral Neuropathy Treatment industry.

This Insight Report provides a comprehensive analysis of the global Chemotherapy Induced Peripheral Neuropathy Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Chemotherapy Induced Peripheral Neuropathy Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Chemotherapy Induced Peripheral Neuropathy Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Chemotherapy Induced Peripheral Neuropathy Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Chemotherapy Induced Peripheral Neuropathy Treatment.

This report presents a comprehensive overview, market shares, and growth opportunities of Chemotherapy Induced Peripheral Neuropathy Treatment market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Calcium Channel α2-delta Ligands
Antidepressants
Opioids
Others

Segmentation by Application:
Platinum Agents
Taxanes
Vinca Alkaloids
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Aptinyx Inc
Asahi Kasei Pharma Corp
Regenacy Pharmaceuticals
MAKScientific LLC
Metys Pharmaceuticals AG
Nemus Bioscience Inc
PledPharma
Sova Pharmaceuticals Inc
DermaXon LLC
Kineta Inc
Krenitsky Pharmaceuticals Inc
PeriphaGen
Apexian Pharma
WinSanTor

Key Questions Addressed in this Report

What is the 10-year outlook for the global Chemotherapy Induced Peripheral Neuropathy Treatment market?

What factors are driving Chemotherapy Induced Peripheral Neuropathy Treatment market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Chemotherapy Induced Peripheral Neuropathy Treatment market opportunities vary by end market size?

How does Chemotherapy Induced Peripheral Neuropathy Treatment break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.